发现Osivelotor (GBT021601):一种强大的下一代状血红蛋白聚合抑制剂
Zhe Li1, Carsten Alt1, Kobina Dufu1
1Pfizer Inc, South San Francisco, California 94080, United States.
ACS medicinal chemistry letters
|August 20, 2025
概括
GBT021601 (osivelotor) 是一种新型的状血红蛋白聚合抑制剂,与voxelotor相比,具有更好的药理动力学特性. 这种下一代疗法在状细胞疾病 (SCD) 治疗方面表现有前途.
科学领域:
- 药理学 药理学是指药理学的学科.
- 血液学 血液学 血液学
- 药物发现 药物发现 药物发现
背景情况:
- 状细胞疾病 (SCD) 是一种遗传性血液疾病,其特征是状血红蛋白 (HbS) 的聚合.
- 目前的治疗方法旨在管理SCD的症状和并发症,并正在研究疾病修饰疗法.
- 作为一流的HbS聚合抑制剂的Voxelotor代表了治疗方面的进步,但药物特性的进一步改进是可取的.
研究的目的:
- 报告GBT021601 (osivelotor) 的发现和临床前表征,这是HbS聚合的新型小分子抑制剂.
- 为了比较GBT021601与voxelotor的药理动力学 (PK) 和药理动力学 (PD) 特性.
- 在SCD的小鼠模型中评估GBT021601的疗效.
主要方法:
- 在大鼠PK研究中,精简的测试漏斗与磁带剂量.
- 在大鼠中对GBT021601和voxelotor进行比较PK分析.
- 在小鼠SCD模型中评估GBT021601对血红蛋白氧化亲和力,红细胞 (RBC) 形,红细胞半衰期和血红蛋白水平的影响.
主要成果:
- 与voxelotor相比,GBT021601表现出显著改善的PK特性,与大约4.8倍的暴露和3.5倍更长的半衰期在老鼠中.
- 在小鼠SCD模型中进行的临床前研究表明,GBT021601增加了血红蛋白的氧 afinity,减少了红细胞形,并增加了红细胞半衰期和血红蛋白水平.
- GBT021601在低于voxelotor的剂量下实现了类似的HbS占用率,这表明治疗负担减少了.
结论:
- GBT021601 (osivelotor) 是一个有前途的下一代HbS聚合抑制剂,具有卓越的PK特性,并在临床前SCD模型中证明有效性.
- GBT021601 改善的 PK/PD 概况可能会降低 SCD 患者的治疗负担.
- 目前GBT021601正在进行SCD治疗的2/3期临床试验.
更多相关视频
07:24A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
1.8K
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
5.1K
相关概念视频
Hemoglobin
4.3K
Hemoglobin is a globular protein made up of four subunits. Two of these subunits are alpha chains, and the other two are beta chains. Each subunit contains a molecule of heme, which has an iron atom and can bind to oxygen. When an oxygen molecule binds to one heme group, it changes the shape of hemoglobin, making it easier for the other heme groups to bind oxygen as well.
When all four heme groups are bound to oxygen, the resulting molecule is called oxyhemoglobin. As a result, arterial blood...
When all four heme groups are bound to oxygen, the resulting molecule is called oxyhemoglobin. As a result, arterial blood...
4.3K
Multiple Allele Traits
34.8K
The Concept of Multiple Allelism
34.8K
Gene Families
9.1K
Gene families consist of groups of genes proposed to have originated from a common ancestor. Typically these arise through events in which a gene or genes are mistakenly duplicated during cell division. Unlike their parent genes (which are subject to selection pressure to maintain function), these gene copies do not need to preserve their sequences and may evolve at a relatively faster rate.
Occasionally these regions can be adapted to take on new roles within the organism, becoming novel genes...
Occasionally these regions can be adapted to take on new roles within the organism, becoming novel genes...
9.1K
Blood Transfusion and Agglutination
11.2K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
11.2K
iPS Cell Differentiation
2.8K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.8K
Enzyme Inhibition
79.5K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
79.5K
